Search PubMed⌕ Search

Biomedical subjects

P Morandi

Publications and source records attributed to P Morandi.

27 records · Page 2Linked to original sources
PubMed1987

High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response.

Clinical response to high-dose medroxyprogesterone (MPA), administered following three different routes of administration (i.m., p.o. + i.m., p.o.) and monitoring drug plasma levels, was evaluated in pretreated advanced breast cancer patients. Fifty-eight of 68 eligible patients were considered evaluable for response. Age ranged between 36 years and 82 years. Fifty-six of 58 evaluable patients were postmenopausal. An overall remission rate of 48% was achieved with i.m. MPA, 50% with combined (i.m. + p.o.) modalities; only a 19% remission rate was recorded in the p.o. group. Response rate and MPA plasma concentrations were correlated, and a drug level of 80 ng/ml, by means of a GLC method, seems to identify a subset of patients with high probability of response. Only mild toxic effects were recorded.

Adult↗
PubMed1987

A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer.

The activity of the association of cis-platinum with Adriamycin and cyclophosphamide (CAP), as "rescue" chemotherapy for the treatment of refractory and relapsing advanced breast cancer, is presented. Of 42 evaluable patients, previously treated with chemotherapy +/- hormone therapy, 4 (9.5%) achieved a complete response, 15 (35%) had a partial response (CR + PR = 45%). Major toxicity observed was: nausea and vomiting in 95% of patients and leukopenia in 60%.

Adult↗
PubMed1986

Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.

A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.

Breast Neoplasms↗
PubMed1985

MPA plasma levels after oral administration in gastrectomized cancer patients during chemotherapy.

Five patients (3 females; 2 males) who underwent gastrectomy for carcinoma were administered adjuvant chemotherapy and high dose medroxyprogesterone acetate (HD-MPA) as supportive therapy. MPA administered p.o. was regularly absorbed; the drug was well tolerated and was almost lacking in toxicity. MPA, thanks to its myeloprotective activity and its anabolic effects, can be used as supportive therapy in the treatment of a wide range of malignancies.

Adenocarcinoma↗
PubMed1984

Chemotherapy of invasive or metastatic thymoma: report of 11 cases.

Eleven patients with invasive thymoma (seven males and four females) were seen from 1977 to 1983. All patients were adults with a median age of 46 years (range, 24-62), and presented after surgical exploration with nonremovable primary and with one or more of the following patterns of tumor extension: supraclavicular lymphadenopathy (four patients), superior vena cava syndrome (two), pleural effusion (nine), and pericardial effusion (three). The following distant metastases were also observed: lung (six patients), liver (one), skin (two), peritoneum (two), bone (one), and brain (one). The chemotherapy was administered in 4-day courses. All patients received the following: 50 mg/m2 of cisplatin iv and 40 mg/m2 of doxorubicin iv on Day 1, 0.6 mg/m2 of vincristine iv on Day 3, and 700 mg/m2 of cyclophosphamide iv on Day 4. The course was repeated every 3 weeks. Toxic effects were tolerable, as expected for the drug combination adopted. Four of 11 patients achieved objective complete regression of disease and six of 11 had partial remission, for an overall response rate of 91%; one patient had stable disease for 7 months. Six patients have died and the median survival has been 12.5 months, ranging from 5 to 23 months.

Adult↗
PubMedDate not supplied

[Urinary excretion of mutagens and cisplatin among the nursing staff at a medical oncology department exposed to cytostatic drugs].

Exposure to cytostatic drugs was assessed in a group of 9 nurses employed in a hospital cancer therapy department by measuring the post-shift levels of urinary mutagens and cis-platinum. A slight but significant increase in urinary mutagenic activity compared to 11 controls was observed in the non-smokers: the mean values of mutagenic activity on the Ta100 strain in the presence of both microsomal and deconjugating enzymes were 4418 +/- 1186 and 2468 +/- 1681 respectively. Conversely, the urinary platinum concentration was below the detection limit of the analytical method (10 micrograms/l) in all samples. The increased urinary mutagenic activity in the exposed group can probably be attributed to the absorption of cyclophosphamide either during preparation and administration of the drug, or due to accidental contact with contaminated biological fluids, in view of the fact that the level of mutagens in urine samples from cyclophosphamide-treated patients is extremely high (up to 319,478 revertants/g creatinine in the case we examined).

Antineoplastic Agents↗
PubMedDate not supplied

Ciliated bodies in ovarian cyst aspirates.

Ciliated bodies, or detached ciliary tufts, are ciliated fragments of cytoplasm from columnar epithelial cells. In gynecologic cytology they have been observed in cervicovaginal smears and peritoneal washings and very occasionally in fluids from the pouch of Douglas. They occur frequently in the fluids of ovarian cysts. The authors detected ciliated bodies in 30 of 326 ovarian cyst fluid samples (9.20% of cases) taken from 27 patients aged 14-68 years. Ciliated bodies were found in the fluids from both bilateral cysts in one patient and in slides from both former and recurrent cysts in two. Surgery was performed in 14 of the cases, with histologic examination revealing 5 simple serous cysts, 3 paraovarian cysts, 3 serous papillary cystoadenofibromas, 1 serous cystoadenoma and 2 mature cystic teratomas. In the remaining cases the pertinent clinical data, including ultrasound ecography, revealed benign paraovarian and ovarian cysts. The existence of ciliated bodies in the fluids of ovarian cysts indicated the presence of ciliated columnar epithelial cells on the wall of the cysts, which would exclude cysts of follicular origin.

Adolescent↗